Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press6810.17650/2313-805X-2016-3-3-30-43REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИSecond primary malignancies in cancer survivors: epidemiology, role of anticancer therapyВторые первичные опухоли у онкологических больных: эпидемиология, роль противоопухолевой терапииSolenovaL. G.СоленоваЛ. Г.
Russian Federation
lsolenova@mail.ruResearch Institute of Carcinogenesis, N. N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaНаучно-исследовательский институт канцерогенеза ФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» Россия, 115478, Москва, Каширское шоссе, 2424 Kashirskoye shosse, Moscow, 115478, Russia150920163330433009201630092016Copyright ©; 2016, Solenova L.G.Copyright ©; 2016, Соленова Л.Г.2016Solenova L.G.Соленова Л.Г.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/68

The recent years have seen considerable advancement in the therapy of oncology patients and hence better survival and longer lifespan. Thus, studies on the distant effects of antitumor therapy have become increasingly important. That particularly concerns the risk of development of the second primary tumors. The patients that received therapy for the first malignant neoplasm become a higher-risk group for the development of a second tumor for their entire subsequent life. The review represents the data of analytical epidemiological studies on the second leukemia and solid tumors caused by the aftereffects of antitumor therapy using alkylating agents. Data are also considered on the risk of the second tumors that developed upon transplantation of stem cells. The second tumor etiology includes other significant risk factors such as genetic predisposition, smoking, alcohol consumption, imbalanced diet, etc. In combination with the aftereffects of antitumor therapy they may influence significantly the probability of the development of the second tumors in cancer patients, which should be considered in developing preventive measures. The review data suggest the need for cooperation of specialists in various fields and the use of clinical, epidemiological and molecular approaches to study the carcinogenesis of the first and second tumors, the choice of efficient and the safest methods of antitumor therapy to reduce the risk of the development of distant aftereffects and their prevention.

cancer patientssecond tumorsrisk factorsanticancer therapyalkylating agentstarget therapypreventionонкологические больныевторые опухолифакторы рискапротивоопухолевая терапияалкилирующие агентытаргетные препаратыпрофилактика1. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Под ред. М. И. Давыдова, Е. М. Аксель. Вестник РОНЦ им. Н. Н. Блохина РАМН 2010;21(2;80). Прил. 1. С. 12. [Staistics of malignant tumors in Russia and CIS countries in 2008. Eds. by: М. I. Davydov, Е. М. Аxel’. Vestnik RONTS im. N. N. Blokhina RAMN = Herald of N. N. Blokhin Russian Cancer Research Center RAMS 2010;21(2;80). Ex. 1. P. 12. (In Russ.)].Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Под ред. М. И. Давыдова, Е. М. Аксель. Вестник РОНЦ им. Н. Н. Блохина РАМН 2010;21(2;80). Прил. 1. С. 12. [Staistics of malignant tumors in Russia and CIS countries in 2008. Eds. by: М. I. Davydov, Е. М. Аxel’. Vestnik RONTS im. N. N. Blokhina RAMN = Herald of N. N. Blokhin Russian Cancer Research Center RAMS 2010;21(2;80). Ex. 1. P. 12. (In Russ.)].2. Состояние онкологической помощи населению России в 2015 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2016. 236 с. [Status of the oncologic assistance to the population of Russia in 2015. Eds. by А. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Мoscow, 2016. 236 p. (In Russ.)].Состояние онкологической помощи населению России в 2015 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2016. 236 с. [Status of the oncologic assistance to the population of Russia in 2015. Eds. by А. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Мoscow, 2016. 236 p. (In Russ.)].3. Verdecchia A., Guzzinati S., Francisci S. et al. EUROCARE Working Group: Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009;45:1042–66.Verdecchia A., Guzzinati S., Francisci S. et al. EUROCARE Working Group: Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009;45:1042–66.4. De Angelis R., Sant M., Coleman M. P. et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE – 5-a population-based study. Lancet Oncol 2014;15(1):23–34.De Angelis R., Sant M., Coleman M. P. et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE – 5-a population-based study. Lancet Oncol 2014;15(1):23–34.5. Travis L. B. Epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15(11):2020–6.Travis L. B. Epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15(11):2020–6.6. Трапезников Н. Н., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ (Состояние онкологической помощи, заболеваемость и смертность). М., 2001. С. 282. [Тrapeznikov N. N., Аksel’ Е. М. Statistics of malignant tumors in Russia and CIS countries (Status of oncologic assistance, morbidity and fatality). Мoscow, 2001. P. 282. (In Russ.)].Трапезников Н. Н., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ (Состояние онкологической помощи, заболеваемость и смертность). М., 2001. С. 282. [Тrapeznikov N. N., Аksel’ Е. М. Statistics of malignant tumors in Russia and CIS countries (Status of oncologic assistance, morbidity and fatality). Мoscow, 2001. P. 282. (In Russ.)].7. Boice J. D. Jr, Curtis R. E., Kleinerman R. A. et al. Multiple primary cancers in Connecticut, 1935–1982. Yale J Biol Med 1986;59(5):533–45.Boice J. D. Jr, Curtis R. E., Kleinerman R. A. et al. Multiple primary cancers in Connecticut, 1935–1982. Yale J Biol Med 1986;59(5):533–45.8. Ng A. K., Bernardo M. V. P., Weller E. et al. Second malignancies after Hodgkin disease treated with radiation therapy with or with out chemotherapy: long-term risks and risk factors. Blood 2002;100:1989–96.Ng A. K., Bernardo M. V. P., Weller E. et al. Second malignancies after Hodgkin disease treated with radiation therapy with or with out chemotherapy: long-term risks and risk factors. Blood 2002;100:1989–96.9. Ильин Н. В., Виноградова Ю. Н. Поздние осложнения больных лимфомой Ходжкина. Практическая онкология 2007;8(2):96–101. [Il’in N.V., Vinogradovа Yu. N. Late complications of the Hodgkin’s lymphoma. Prakticheskaya onkologiya = Practical Oncology 2007;8(2):96–101. (In Russ.)].Ильин Н. В., Виноградова Ю. Н. Поздние осложнения больных лимфомой Ходжкина. Практическая онкология 2007;8(2):96–101. [Il’in N.V., Vinogradovа Yu. N. Late complications of the Hodgkin’s lymphoma. Prakticheskaya onkologiya = Practical Oncology 2007;8(2):96–101. (In Russ.)].10. Ng A. K., Travis L. B. Subsequent malignant neoplasms in cancer survivors. Cancer J 2008;14(6):429–34.Ng A. K., Travis L. B. Subsequent malignant neoplasms in cancer survivors. Cancer J 2008;14(6):429–34.11. Soerjomataram I., Coebergh J. W. Epidemiology of multiple primary cancers. Methods Mol Biol 2009;471:85–105.Soerjomataram I., Coebergh J. W. Epidemiology of multiple primary cancers. Methods Mol Biol 2009;471:85–105.12. Шунько Е. Л. Лучевая и химиотерапия как факторы развития первично-множественных злокачественных новообразований (Обзор литературы). Современные проблемы науки и образования 2011;6. Доступно по: http://www.science-educatin.ru/ru/article/view&id=5269. [Shun’ko Е. L. Radial and chemical therapy as factors of development of multiple primary neoplasms (Literature review). Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education 2011;6. Available at: http://www.science-educatin.ru/ru/article/view&id=5269. (In Russ.)].Шунько Е. Л. Лучевая и химиотерапия как факторы развития первично-множественных злокачественных новообразований (Обзор литературы). Современные проблемы науки и образования 2011;6. Доступно по: http://www.science-educatin.ru/ru/article/view&id=5269. [Shun’ko Е. L. Radial and chemical therapy as factors of development of multiple primary neoplasms (Literature review). Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education 2011;6. Available at: http://www.science-educatin.ru/ru/article/view&id=5269. (In Russ.)].13. Ханов А. М. Современные представления о первично-множественных опухолях. Классификации. Доступно по: http//travelexpress. lt/obschaja-onkologija/pervichno-mnozhestiennyje-opuholi.html. [Khanov А. М. Modern perceptions of multiple primary neoplasms. Classifications. Available at: http//travelexpress. lt/obschaja-onkologija/pervichno-mnozhestiennyje-opuholi.html. (In Russ.)].Ханов А. М. Современные представления о первично-множественных опухолях. Классификации. Доступно по: http//travelexpress. lt/obschaja-onkologija/pervichno-mnozhestiennyje-opuholi.html. [Khanov А. М. Modern perceptions of multiple primary neoplasms. Classifications. Available at: http//travelexpress. lt/obschaja-onkologija/pervichno-mnozhestiennyje-opuholi.html. (In Russ.)].14. Заева Г. Е., Михайлова С. Н. Вторые опухоли у детей, излеченных от злокачественных новообразований. Детская онкология. Национальное руководство. Под ред. М. Д. Алиева, В. Г. Полякова, Г. Л. Менткевича, С. А. Маяковой. М., 2012. С. 640–649. [Zaevа G. Е., Мikhaylovа S. N. Repeated tumors at children, cured from malignant tumors. Children’s oncology. National guidelines. Eds. by: М. D. Аliev, V. G. Polyakov, G. L. Меntkevich, S. А. Маyakova. Мoscow, 2012. Pp. 640–649. (In Russ.)].Заева Г. Е., Михайлова С. Н. Вторые опухоли у детей, излеченных от злокачественных новообразований. Детская онкология. Национальное руководство. Под ред. М. Д. Алиева, В. Г. Полякова, Г. Л. Менткевича, С. А. Маяковой. М., 2012. С. 640–649. [Zaevа G. Е., Мikhaylovа S. N. Repeated tumors at children, cured from malignant tumors. Children’s oncology. National guidelines. Eds. by: М. D. Аliev, V. G. Polyakov, G. L. Меntkevich, S. А. Маyakova. Мoscow, 2012. Pp. 640–649. (In Russ.)].15. Marcheselli R., Marcheselli L., Cortesi L. et al. Risk of second malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer 2015;18(4):374– 85.Marcheselli R., Marcheselli L., Cortesi L. et al. Risk of second malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer 2015;18(4):374– 85.16. Multiple primary cancers in Connecticut and Denmark. Eds by: J. D. Jr Boice, H. H. Storm, R. E. Curtis et al. Natl Cancer Inst Monogr 1985;68:1–437.Multiple primary cancers in Connecticut and Denmark. Eds by: J. D. Jr Boice, H. H. Storm, R. E. Curtis et al. Natl Cancer Inst Monogr 1985;68:1–437.17. Krueger H., McLean D., Willians D. The prevention of second primary cancers. Prog Exp Tumor Res. Basel; New York; Karder, 2008. 147 р.Krueger H., McLean D., Willians D. The prevention of second primary cancers. Prog Exp Tumor Res. Basel; New York; Karder, 2008. 147 р.18. IARC International rules for multiple primary cancers. Working group. Lyon: IARC, 2004. Eur J Canc Prev 2005;14(4):307–8.IARC International rules for multiple primary cancers. Working group. Lyon: IARC, 2004. Eur J Canc Prev 2005;14(4):307–8.19. Molina-Montes E., Requena M., Sanchez-Cantalejo E. et al. Risk of second cancer after a first primary breast cancer: A systematic review and meta-analysis. Gyn Oncol 2014. Available at: http://dx.doi.org/10.1016/jgyno. 2014.10.029.Molina-Montes E., Requena M., Sanchez-Cantalejo E. et al. Risk of second cancer after a first primary breast cancer: A systematic review and meta-analysis. Gyn Oncol 2014. Available at: http://dx.doi.org/10.1016/jgyno. 2014.10.029.20. Hemminki K., Boffetta P. Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. IARC scientific publications 2004;157:289–97.Hemminki K., Boffetta P. Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. IARC scientific publications 2004;157:289–97.21. Сельчук В. Ю. Первично-множественные злокачественные опухоли (клиника, лечение и закономерности развития). Автореф. дис. … д-ра мед. наук. М., 1994. 70 с. [Sel’chuk V. Yu. Multiple primary neoplasms (clinic, treatment and laws of development). Author’s abstreact of thesis … of doctor of medical sciences. Мoscow, 1994. 70 p. (In Russ.)].Сельчук В. Ю. Первично-множественные злокачественные опухоли (клиника, лечение и закономерности развития). Автореф. дис. … д-ра мед. наук. М., 1994. 70 с. [Sel’chuk V. Yu. Multiple primary neoplasms (clinic, treatment and laws of development). Author’s abstreact of thesis … of doctor of medical sciences. Мoscow, 1994. 70 p. (In Russ.)].22. Кашурников А. Ю. Первично-множественные злокачественные новообразования органов репродуктивной системы толстой кишки у женщин: закономерности развития, диагностика и прогноз. Автореф. дис. … канд. мед. наук. М., 2015. 25 с. [Kashurnikov А. Yu. Multiple primary neoplasms of the large bowel of the reproductive system at women: laws of development, diagnosis and forecast. Author’s abstreact of thesis … of candidate medical sciences. Мoscow, 2015. 25 p. (In Russ.)].Кашурников А. Ю. Первично-множественные злокачественные новообразования органов репродуктивной системы толстой кишки у женщин: закономерности развития, диагностика и прогноз. Автореф. дис. … канд. мед. наук. М., 2015. 25 с. [Kashurnikov А. Yu. Multiple primary neoplasms of the large bowel of the reproductive system at women: laws of development, diagnosis and forecast. Author’s abstreact of thesis … of candidate medical sciences. Мoscow, 2015. 25 p. (In Russ.)].23. Soto A. M., Sonnenschein С. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays 2011;33(5):332–40.Soto A. M., Sonnenschein С. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays 2011;33(5):332–40.24. Бабаян А. Ю., Залетаев Д. В., Немцова М. В. Подтверждение значения теории полей канцеризации в генезе поверхностного рака мочевого пузыря. Молекулярная медицина 2013;1:24–8. [Babayan А. Yu., Zaletaev D. V., Nemtsovа М. V. Confirmation of the value of the cancerization fields’ theory in the genesis of the superficial bladder cancer. Моlekulyarnaya meditsina = Моlecular Medicine 2013;1:24–8. (In Russ.)].Бабаян А. Ю., Залетаев Д. В., Немцова М. В. Подтверждение значения теории полей канцеризации в генезе поверхностного рака мочевого пузыря. Молекулярная медицина 2013;1:24–8. [Babayan А. Yu., Zaletaev D. V., Nemtsovа М. V. Confirmation of the value of the cancerization fields’ theory in the genesis of the superficial bladder cancer. Моlekulyarnaya meditsina = Моlecular Medicine 2013;1:24–8. (In Russ.)].25. Ford M. B., Sigurdson A. J., Petrulis E. S. et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 2003;98(7):1457–64.Ford M. B., Sigurdson A. J., Petrulis E. S. et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 2003;98(7):1457–64.26. Druesne-Pecollo N., Touvier M., Barrandon E. et al. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat 2012;135(3):647–54.Druesne-Pecollo N., Touvier M., Barrandon E. et al. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat 2012;135(3):647–54.27. Morton L. M., Swerdlow A. J., Schaapveld M. et al. Current knowledge and future research directions in treatment-related second primary malignancies. EJC Suppl 2014;12(1):5–17.Morton L. M., Swerdlow A. J., Schaapveld M. et al. Current knowledge and future research directions in treatment-related second primary malignancies. EJC Suppl 2014;12(1):5–17.28. Mellemkjaer L., Friis S., Olsen J. H. et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006;18(9):2285–92.Mellemkjaer L., Friis S., Olsen J. H. et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006;18(9):2285–92.29. Онкология. Под ред. Д. Касчиато. М.: Практика, 2008. 1039 с. [Оncology. Ed. by D. Caschiatо. Мoscow: Praktika, 2008. 1039 p. (In Russ.)].Онкология. Под ред. Д. Касчиато. М.: Практика, 2008. 1039 с. [Оncology. Ed. by D. Caschiatо. Мoscow: Praktika, 2008. 1039 p. (In Russ.)].30. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н. И. Переводчиковой, В. А. Горбуновой. М.: Практическая медицина, 2015. 686 с. [Guidelines on the chemical therapy of malignant diseases. Eds. by: N. I. Perevodchikova, V. А. Gorbunova. Мoscow: Prakticheskaya meditsina, 2015. 686 p. (In Russ.)].Руководство по химиотерапии опухолевых заболеваний. Под ред. Н. И. Переводчиковой, В. А. Горбуновой. М.: Практическая медицина, 2015. 686 с. [Guidelines on the chemical therapy of malignant diseases. Eds. by: N. I. Perevodchikova, V. А. Gorbunova. Мoscow: Prakticheskaya meditsina, 2015. 686 p. (In Russ.)].31. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н. И. Переводчиковой. М.: Практическая медицина, 2011. 511 с. [Guidelines on the chemical therapy of tumor diseases. Ed. by N. I. Perevodchikova. Мoscow: Prakticheskaya meditsina, 2011. 511 p. (In Russ.)].Руководство по химиотерапии опухолевых заболеваний. Под ред. Н. И. Переводчиковой. М.: Практическая медицина, 2011. 511 с. [Guidelines on the chemical therapy of tumor diseases. Ed. by N. I. Perevodchikova. Мoscow: Prakticheskaya meditsina, 2011. 511 p. (In Russ.)].32. Tsai H. J., Wu C. C., Tsai C. R. et al. Second cancers in patients with neuroendocrine tumors. PLoS One 2013;8(12):e86414.Tsai H. J., Wu C. C., Tsai C. R. et al. Second cancers in patients with neuroendocrine tumors. PLoS One 2013;8(12):e86414.33. Lee D. H., Roh J. L., Baek S. et al. Second cancer incidence, risk factors, and specific mortality in head and neck squamous cell carcinoma. J Gastroenterol 2014;49(5):843–52.Lee D. H., Roh J. L., Baek S. et al. Second cancer incidence, risk factors, and specific mortality in head and neck squamous cell carcinoma. J Gastroenterol 2014;49(5):843–52.34. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Eds. by: R. E. Curtis, D. M. Freedman, E. Ron et al. National Cancer Institute. NIH Publ. No 05–5302. Bethesda, MD, 2006.New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Eds. by: R. E. Curtis, D. M. Freedman, E. Ron et al. National Cancer Institute. NIH Publ. No 05–5302. Bethesda, MD, 2006.35. Omer B., Kadan-Lottick N. S., Roberta K. B. et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematol 2012;158:615–25.Omer B., Kadan-Lottick N. S., Roberta K. B. et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematol 2012;158:615–25.36. Tajika M., Matsuo K., Ito H. et al. Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT). J Gastroenterol 2014;49(5):843–52.Tajika M., Matsuo K., Ito H. et al. Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT). J Gastroenterol 2014;49(5):843–52.37. Haase D., Hanf V., Schulz T. Therapyrelated hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results. Med Klin (Munich) 2004;99(9):506–17.Haase D., Hanf V., Schulz T. Therapyrelated hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results. Med Klin (Munich) 2004;99(9):506–17.38. Momota H., Narita Y., Miyakita Y., Shibui S. Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 2013;15(10):1445–50.Momota H., Narita Y., Miyakita Y., Shibui S. Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 2013;15(10):1445–50.39. Travis L. B., Holowaly E., Hall P. et al. Risk of leukemia following platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351–7.Travis L. B., Holowaly E., Hall P. et al. Risk of leukemia following platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351–7.40. IARC Monographs on the evaluation of carcinogenic risk to humans. Some antiviral and antineoplastic drugs, and other pharmaceutical agents. Lyon, 2000;76:177–239.IARC Monographs on the evaluation of carcinogenic risk to humans. Some antiviral and antineoplastic drugs, and other pharmaceutical agents. Lyon, 2000;76:177–239.41. Jaffe E. S., Harris N. L., Stein H., Vardiman J. W. World Health Organization classification of tumours: pathology and genetics of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.Jaffe E. S., Harris N. L., Stein H., Vardiman J. W. World Health Organization classification of tumours: pathology and genetics of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.42. Schaapveld M., Aleman B. M.P., van Eggermond A. M. et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 2015;373:2499–511.Schaapveld M., Aleman B. M.P., van Eggermond A. M. et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 2015;373:2499–511.43. Travis L. B., Gospodarowicz M., Curtis R. E. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002;94(3):182–93.Travis L. B., Gospodarowicz M., Curtis R. E. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002;94(3):182–93.44. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. IARC Monogr Eval Carcinoq Risks Hum 2012;100(A)1–401.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. IARC Monogr Eval Carcinoq Risks Hum 2012;100(A)1–401.45. Curtis R. E., Boice Jr J.D., Shriner D. A. et al. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88(12):832–4.Curtis R. E., Boice Jr J.D., Shriner D. A. et al. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88(12):832–4.46. Curtis R. E., Freedman D. M., Sherman M. E., Fraumeni Jr J.F. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. JNCI J Natl Cancer Inst 2004;96(1):70–4.Curtis R. E., Freedman D. M., Sherman M. E., Fraumeni Jr J.F. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. JNCI J Natl Cancer Inst 2004;96(1):70–4.47. Matesich S. M., Shapiro C. L. Second cancers after breast cancer treatment. Semin Oncol 2003;30(6):740–8.Matesich S. M., Shapiro C. L. Second cancers after breast cancer treatment. Semin Oncol 2003;30(6):740–8.48. Статистика злокачественных новообразований в России и странах СНГ в 2013 г. Под ред. М. И. Давыдова, Е. М. Аксель. М., 2015. С. 14. [Statistics of malignant tumors in Russian and CIS countries in 2013. Eds. by: М. I. Davydov, Е. М. Аksel’. Мoscow, 2015. P. 14. (In Russ.).Статистика злокачественных новообразований в России и странах СНГ в 2013 г. Под ред. М. И. Давыдова, Е. М. Аксель. М., 2015. С. 14. [Statistics of malignant tumors in Russian and CIS countries in 2013. Eds. by: М. I. Davydov, Е. М. Аksel’. Мoscow, 2015. P. 14. (In Russ.).49. Valdivieso M., Kujawa A. M., Jones T., Baker L. H. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci 2012;9:163–73.Valdivieso M., Kujawa A. M., Jones T., Baker L. H. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci 2012;9:163–73.50. Meadows A. T., Friedman D. L., Neglia J. P. et al. Second neoplasms in survivors of childhood cancer: finding from the Childhood Cancer Survivor Study Cohort. J Clinic Oncol 2009;27(14):2356–62.Meadows A. T., Friedman D. L., Neglia J. P. et al. Second neoplasms in survivors of childhood cancer: finding from the Childhood Cancer Survivor Study Cohort. J Clinic Oncol 2009;27(14):2356–62.51. Щербенко О. И. Вторые опухоли у лиц, подвергавшихся противоопухолевой терапии в детском возрасте. Статистика, этиология, пути профилактики. Доступно по: http://vestnik.rncrr.ru/vestnik/v13/paper/sherbenko_v13. htm. [Shcherbenko О. I. Second tumors at people, undergoing the antitumor therapy in childhood. Statistics, etiology, prophylactic methods. Available at: http://vestnik.rncrr.ru/vestnik/v13/paper/sherbenko_v13. htm. (In Russ.)].Щербенко О. И. Вторые опухоли у лиц, подвергавшихся противоопухолевой терапии в детском возрасте. Статистика, этиология, пути профилактики. Доступно по: http://vestnik.rncrr.ru/vestnik/v13/paper/sherbenko_v13. htm. [Shcherbenko О. I. Second tumors at people, undergoing the antitumor therapy in childhood. Statistics, etiology, prophylactic methods. Available at: http://vestnik.rncrr.ru/vestnik/v13/paper/sherbenko_v13. htm. (In Russ.)].52. Кулева С. А., Колыгин Б. А. Вторые опухоли, возникшие после терапии злокачественных опухолей у детей. Вопросы онкологогии 2012;58(5):606–15. [Kulevа S. А., Kolygin B. А. Second tumors, arising after the therapy of malignant tumors at children. Voprosy onkologii = Oncology Issues 2012;58(5):606–15. (In Russ.)].Кулева С. А., Колыгин Б. А. Вторые опухоли, возникшие после терапии злокачественных опухолей у детей. Вопросы онкологогии 2012;58(5):606–15. [Kulevа S. А., Kolygin B. А. Second tumors, arising after the therapy of malignant tumors at children. Voprosy onkologii = Oncology Issues 2012;58(5):606–15. (In Russ.)].53. Субботина Н. Н., Долгополов И. Г., Менткевич Г. Л. Трансплантация гемопоэтических стволовых клеток. Детская онкология. Национальное руководство. Под ред. М. Д. Алиева, В. Г. Полякова, Г. Л. Менткевича, С. А. Маяковой. М.: Издательская группа РОНЦ, 2012. С. 261–272. [Subbotinа N. N., Dolgopolov I. G., Меntkevich G. L. Transplantation of hemapoietic of stem cells. Children’s oncology. National guidelines. Eds. by: М. D. Аliev, V. G. Polyakov, G. L. Меntkevich, S. А. Маyakova. Мoscow: Izdatel’skaya gruppa RONTS, 2012. Pp. 261–272. (In Russ.)].Субботина Н. Н., Долгополов И. Г., Менткевич Г. Л. Трансплантация гемопоэтических стволовых клеток. Детская онкология. Национальное руководство. Под ред. М. Д. Алиева, В. Г. Полякова, Г. Л. Менткевича, С. А. Маяковой. М.: Издательская группа РОНЦ, 2012. С. 261–272. [Subbotinа N. N., Dolgopolov I. G., Меntkevich G. L. Transplantation of hemapoietic of stem cells. Children’s oncology. National guidelines. Eds. by: М. D. Аliev, V. G. Polyakov, G. L. Меntkevich, S. А. Маyakova. Мoscow: Izdatel’skaya gruppa RONTS, 2012. Pp. 261–272. (In Russ.)].54. Афанасьев Б. В., Зубаровская Л. С., Моисеев И. С. Аллогенная трансплантация гемопоэтических стволовых клеток у детей: настоящее, проблемы, перспективы. Российский журнал детской гематологии и онкологии 2015;2(2):28–42. [Аfanas’ev B.V., Zubarovaskaya L. S., Моiseev I. S. Аllogeneic stem cell transplantation of hemapoietic stem cells at children: present time, challenges, prospects. Russiiskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Children’s Hematology and Oncology 2015;2(2):28–42. (In Russ.)].Афанасьев Б. В., Зубаровская Л. С., Моисеев И. С. Аллогенная трансплантация гемопоэтических стволовых клеток у детей: настоящее, проблемы, перспективы. Российский журнал детской гематологии и онкологии 2015;2(2):28–42. [Аfanas’ev B.V., Zubarovaskaya L. S., Моiseev I. S. Аllogeneic stem cell transplantation of hemapoietic stem cells at children: present time, challenges, prospects. Russiiskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Children’s Hematology and Oncology 2015;2(2):28–42. (In Russ.)].55. Passweg J. R., Baldomero H., Bader P. et al. Hematopoetic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord transplants. Bone Marrow Transplantation 2015;50:476–82.Passweg J. R., Baldomero H., Bader P. et al. Hematopoetic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord transplants. Bone Marrow Transplantation 2015;50:476–82.56. Gratwohl A., Sureda A., Baldomero H. et al. Economics and outcome after hematopoietic stem cell transplantation: a retrospective cohort study. EBioMedicine 2015;2(12):2101–9.Gratwohl A., Sureda A., Baldomero H. et al. Economics and outcome after hematopoietic stem cell transplantation: a retrospective cohort study. EBioMedicine 2015;2(12):2101–9.57. Forrest D. L., Hogge D. E., Nevil T. J. et al. High-dose therapy and autologous hematopoeietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: a compar ison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 2005;23(31):7994–8002.Forrest D. L., Hogge D. E., Nevil T. J. et al. High-dose therapy and autologous hematopoeietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: a compar ison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 2005;23(31):7994–8002.58. Pedersen-Bjergaard J., Andersen M. K., Christiansen D. H. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273–9.Pedersen-Bjergaard J., Andersen M. K., Christiansen D. H. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273–9.59. Kalaycio M., Rybicki L., Pohlman B. et al. Risk factors before autologous stem-cell transplantation for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006;24(22):3604–10.Kalaycio M., Rybicki L., Pohlman B. et al. Risk factors before autologous stem-cell transplantation for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006;24(22):3604–10.60. Jagadeesh D., Woda B. A., Draper J., Evens A. M. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012;13:122–36.Jagadeesh D., Woda B. A., Draper J., Evens A. M. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012;13:122–36.61. Lowe T., Bhatia S., Somlo G. Second malignancies after allogenic hematopoietic cell transplantation. Biolof Blood Marrow Transplant 2007;13:1121–34.Lowe T., Bhatia S., Somlo G. Second malignancies after allogenic hematopoietic cell transplantation. Biolof Blood Marrow Transplant 2007;13:1121–34.62. Majhail N. S., Brazauskas R., Rizzo J. D. et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011;117(1):316–22.Majhail N. S., Brazauskas R., Rizzo J. D. et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011;117(1):316–22.63. Grosse Y., Baan R., Straif K. et al. Special report: policy. A review of human carcinogens – Part A: Pharmaceuticals. Available at: www/thelancet.com/oncologyGrosse Y., Baan R., Straif K. et al. Special report: policy. A review of human carcinogens – Part A: Pharmaceuticals. Available at: www/thelancet.com/oncology64. IARC Monographs on the evaluation of carcinogenic risk to humans.monographs.iarc.fr/ENG/Classification/List of classification. pdf.IARC Monographs on the evaluation of carcinogenic risk to humans.monographs.iarc.fr/ENG/Classification/List of classification. pdf.65. Корман Д. Б. Мишени и механизмы действия противоопухолевых препаратов. М.: Практическая медицина, 2014. 320 с. [Korman D. B. Targets and mechanisms of antitumor drugs’ effect. Мoscow: Practicheskaya meditsina, 2014. 320 p. (In Russ.)].Корман Д. Б. Мишени и механизмы действия противоопухолевых препаратов. М.: Практическая медицина, 2014. 320 с. [Korman D. B. Targets and mechanisms of antitumor drugs’ effect. Мoscow: Practicheskaya meditsina, 2014. 320 p. (In Russ.)].66. Iacovelli R., Pietrantonio F., Farcomeni A. et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One 2014;9(9):e108940.Iacovelli R., Pietrantonio F., Farcomeni A. et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One 2014;9(9):e108940.67. Новые возможности таргетной терапии метастатического колоректального рака. Онкология сегодня 2016;(2):10–1. [New opportunities of the target therapy of the metastatic colorectal cancer. Оncologiya segodnya = Оncology Today 2016;(2):10–1. (In Russ.)].Новые возможности таргетной терапии метастатического колоректального рака. Онкология сегодня 2016;(2):10–1. [New opportunities of the target therapy of the metastatic colorectal cancer. Оncologiya segodnya = Оncology Today 2016;(2):10–1. (In Russ.)].68. Widakowich C., de Castro G. Jr, de Azambuja E. et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443–55.Widakowich C., de Castro G. Jr, de Azambuja E. et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443–55.69. Kaplan W. Background paper 6.5. Cancer and cancer therapeutics. Priority Medicines for Europe and the World. Geneva: World Health Organization in collaboration with Utrecht University and Boston University, 2013.Kaplan W. Background paper 6.5. Cancer and cancer therapeutics. Priority Medicines for Europe and the World. Geneva: World Health Organization in collaboration with Utrecht University and Boston University, 2013.70. Ильницкий А. П. Первичная профилактика рака: место и роль в противораковой борьбе. Информационный бюллетень. М., 2005. Вып. 1. С. 4–6. [Il’nitskiy А. P. Initial prophylactics of cancer: place and role in the fight against cancer. News-bulletin. Мoscow, 2005. Ed. 1. Pp. 4–6. (In Russ.)].Ильницкий А. П. Первичная профилактика рака: место и роль в противораковой борьбе. Информационный бюллетень. М., 2005. Вып. 1. С. 4–6. [Il’nitskiy А. P. Initial prophylactics of cancer: place and role in the fight against cancer. News-bulletin. Мoscow, 2005. Ed. 1. Pp. 4–6. (In Russ.)].71. Методические рекомендации. Модель региональной программы первичной профилактики рака. МР 2.2.9.0012–10. М., 2010. [Меthodological recommendations. Model of the regional program of the primary cancer prevention. МР 2.2.9.0012–10. Мoscow, 2010. (In Russ.)].Методические рекомендации. Модель региональной программы первичной профилактики рака. МР 2.2.9.0012–10. М., 2010. [Меthodological recommendations. Model of the regional program of the primary cancer prevention. МР 2.2.9.0012–10. Мoscow, 2010. (In Russ.)].72. Федеральный закон от 30.03.1999 N 52-ФЗ (ред. от 03.07.2016) «О санитарно-эпидемиологическом благополучии населения». [Federal law dated 30.03.1999 No 52- ФЗ (ed. оf 03.07.2016) “Оn the Sanitary & Epidemiologic Welfare of the Population”. (In Russ.)].Федеральный закон от 30.03.1999 N 52-ФЗ (ред. от 03.07.2016) «О санитарно-эпидемиологическом благополучии населения». [Federal law dated 30.03.1999 No 52- ФЗ (ed. оf 03.07.2016) “Оn the Sanitary & Epidemiologic Welfare of the Population”. (In Russ.)].73. Schuz J., Espina C., Villiain P. et al. European Code against cancer 4th edn.: 12 ways to reduce your cancer risk. Cancer Epidemiol 2015;39(Suppl 1):1–10.Schuz J., Espina C., Villiain P. et al. European Code against cancer 4th edn.: 12 ways to reduce your cancer risk. Cancer Epidemiol 2015;39(Suppl 1):1–10.74. Первичная профилактика рака. Доступно по: www.ppr-info.ru. [Primary cancer prevention. Available at: www.ppr-info.ru.(In Russ.)].Первичная профилактика рака. Доступно по: www.ppr-info.ru. [Primary cancer prevention. Available at: www.ppr-info.ru.(In Russ.)].75. Travis L. B., Wahnefried W. D., Allan J. M. et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289–301.Travis L. B., Wahnefried W. D., Allan J. M. et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289–301.76. Rosenthal A., Jacobs I. Familial ovarian cancer screening. Best Pract Res Clin Obstet Gynaecol 2006;20:321–38.Rosenthal A., Jacobs I. Familial ovarian cancer screening. Best Pract Res Clin Obstet Gynaecol 2006;20:321–38.77. Nekhlyudov L., Aziz N. M., Lerro C., Virgo K. S. Oncologists’ and primary care physicians» awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. JOP 2014;10(2):29–36.Nekhlyudov L., Aziz N. M., Lerro C., Virgo K. S. Oncologists’ and primary care physicians» awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. JOP 2014;10(2):29–36.78. Freedman A. N., Seminara D., Gail M. H. et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005;97(10):715–23.Freedman A. N., Seminara D., Gail M. H. et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005;97(10):715–23.79. Elena J. W., Travis L. B., Simonds N. I. et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst 2013;105(2):85–94.Elena J. W., Travis L. B., Simonds N. I. et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst 2013;105(2):85–94.